Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

4 articles from the last 30 days matching "motor neurons"

Clinical trialRSS5 days ago

Neurizon gets OK to test liquid form of ALS medication in Australia

A company called Neurizon Therapeutics has been approved to test a new liquid version of a drug called NUZ-001 in Australia. This drug is being developed to treat ALS, a disease that affects nerve cells and causes muscle weakness. The company is testing this liquid form in healthy volunteers, while a tablet version of the same drug is already being tested in a larger trial in the United States.

WHY IT MATTERSIf the liquid formulation proves safe and effective, it could offer ALS patients an easier-to-take alternative to a tablet, which may improve medication adherence for people with swallowing difficulties—a common symptom of ALS.
👁 Watch this spaceamyotrophic lateral sclerosis
Clinical trialRSSMay 4

Dazucorilant shows significant survival benefit in Phase 2 ALS trial

A new experimental drug called dazucorilant helped people with ALS live longer when given at a higher dose, according to a Phase 2 clinical trial. While the trial didn't fully meet all its main goals, the survival benefit was significant enough to be noteworthy. This suggests the drug may have promise for treating ALS, a disease that affects nerve cells controlling muscles.

WHY IT MATTERSIf dazucorilant advances to Phase 3 testing, ALS patients may have access to a new treatment option that could extend survival, which is critical since current ALS therapies have limited effectiveness.
👁 Watch this spaceamyotrophic lateral sclerosis
Clinical trialRSSApr 30

Developer gets OK to expand first-in-human trial of ALS therapy to Europe

A company called Vectory Therapeutics has received permission to test its experimental ALS drug, called VTx-002, at hospitals in the United Kingdom and European Union. The drug is already being tested in the United States as part of a Phase 1/2 clinical trial. This expansion means more patients in Europe may have the opportunity to participate in this early-stage study of a potential new ALS treatment.

WHY IT MATTERSALS patients in the U.K. and EU now have access to a first-in-human trial for a novel therapy, potentially expanding treatment options beyond currently available medications for this rapidly progressive disease.
💬 Ask your doctoramyotrophic lateral sclerosis
Clinical trialRSSApr 28

RAG-17 shows promise in SOD1-ALS trial, reducing damage markers

Scientists are testing a new drug called RAG-17 for people with a specific type of ALS (a disease that weakens muscles over time) caused by a SOD1 gene mutation. Early results show the drug was safe at different doses and made important disease markers improve. This is early-stage testing, but it's a promising first step.

WHY IT MATTERSIf you have SOD1-ALS, this is one of the first treatments specifically designed for your genetic form of the disease, and early signs suggest it may slow the damage happening in your body.
💬 Ask your doctoramyotrophic lateral sclerosis (SOD1-ALS)

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases